- Home » News and EventsPage 13
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Patient-Centric Trial Supply Solutions to be Discussed by Catalent Experts at Virtual Industry Events
Mar 16, 2021
Catalent today announced that two of its clinical supply experts will be participating in upcoming digital events, Clinical Trial Supply Europe and Clinical Trial Supply Roundtable Forum 2021.
Catalent joins the EuropaBio 25th Anniversary in 2021
Mar 9, 2021
EuropaBio today announced that Catalent has joined EuropaBio’s 25th Anniversary Celebration Programme as a major sponsor.
Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities
Feb 23, 2021
Together, the addition of pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy.
Catalent Announces Commercial Supply Agreement with Aurinia Pharmaceuticals for Newly-Approved LUPKYNIS™ Softgels
Feb 18, 2021
Catalent today announced that it recently signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals, for LUPKYNIS™ (voclosporin), a drug to treat adult patients with lupus nephritis (LN).
Catalent Completes Acquisition of Dry Powder Inhaler Spray Drying, Capsule Manufacturing, and Packaging Capabilities from Acorda Therapeutics
Feb 15, 2021
Catalent has completed the acquisition of the manufacturing and packaging operations of Acorda Therapeutics, Inc., a developer of therapies to restore function and improve the lives of people with neurological disorders.
Catalent Launches CosmoPod® Duo – New Dual Chamber Capsule for Beauty and Consumer Health Topical Applications
Feb 9, 2021
Catalent today announced the launch of its CosmoPod® Duo softgel capsule technology for the delivery of topical skin treatments.
Catalent Signs Development and Manufacturing Agreement with Trizell for Macrophage-based Advanced Cell Therapy
Feb 8, 2021
Catalent today announced that it had signed an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies.
Decibel and Catalent Sign Development and Manufacturing Agreement for Dual-Vector Gene Therapy for the Treatment of Congenital Hearing Loss
Feb 4, 2021
Catalent and Decibel Therapeutics today announced they have signed an agreement for Catalent to provide Decibel with process and analytical development, and CGMP clinical manufacturing services, for Decibel’s lead investigational gene therapy product candidate, DB-OTO.
Catalent Recognized as a Country Certified Top Employer 2021
Jan 25, 2021
Catalent today announced that it has been officially recognized by the Top Employers Institute as a Top Employer 2021 in the United States.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.